Boey® is described as the first and only rapid-onset, short-duration botulinum neurotoxin serotype E product approved in Europe for temporary improvement of glabellar lines. The company claims results can appear as early as 8 hours post-treatment and typically wear off within the shorter duration typical of “short-duration” formulations.
Boey® is described as the first and only rapid-onset, short-duration botulinum neurotoxin serotype E product approved in Europe for temporary improvement of glabellar lines. The company claims results can appear as early as 8 hours post-treatment and typically wear off within the shorter duration typical of “short-duration” formulations.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
mildly positive
Sentiment Score
0.25
